Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures
Multiple Sclerosis Journal - Experimental, Translational and Clinical · 01.09.2015 · 1
DOI: 10.1177/2055217315623800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal - Experimental, Translational and Clinical, online erschienen am 24.12.2015. Verfasst von Enrique Alvarez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University School of Medicine in St Louis, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCRR NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
B-cell depleting drugs show promise for treating multiple sclerosis.
Objective
We sought predictors of optimal response to rituximab, a B-cell depleting antibody, to help guide therapy selection.
Methods
We performed a post hoc study of 30 relapsing multiple sclerosis patients with breakthrough disease while on beta-interferon or glatiramer acetate who were treated with add-on rituximab. Standardized neurologic examinations, brain magnetic resonance imaging, and cerebrospinal fluid were obtained before and after rituximab. Tissue biomarkers were measured. Optimal responders were defined as having no evidence of disease activity.
Results
At baseline, optimal responders with no evidence of disease activity had higher IgG indices ( P = 0.041), and higher CXCL13 indices ((cerebrospinal fluid CXCL13/serum CXCL13)/albumin index; P = 0.024), more contrast enhancing lesions ( P = 0.002), better 25 foot timed walk ( P = 0.001), and Expanded Disability Status Scale ( P = 0.002). Rituximab treatment led to reduced cerebrospinal fluid biomarkers of tissue destruction: myelin basic protein ( P = 0.046), neurofilament light chain ( P < 0.001), and of inflammation (CXCL13 index; P = 0.042).
Conclusions
Multiple sclerosis patients with optimal response to rituximab had higher cerebrospinal fluid IgG and CXCL13 indices, more gadolinium-enhancing lesions, and less disability at baseline. Rituximab treatment led to decreased markers of inflammation and tissue damage. If validated, these results will help identify multiple sclerosis patients who will respond optimally to B-cell depletion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Washington University School of Medicine in St Louis, USA.
- Biostatistics Shared Resource, Washington University School of Medicine in St Louis, USA.
Förderung
- NINDS NIH HHS
- NCRR NIH HHS
- NCATS NIH HHS
- Intramural NIH HHS
Zitieren
APA
Alvarez, E., Piccio, L., Mikesell, R. J., Trinkaus, K., Parks, B. J., Naismith, R. T., & Cross, A. H. (2015). Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 1. https://doi.org/10.1177/2055217315623800
Vancouver
Alvarez E, Piccio L, Mikesell RJ, Trinkaus K, Parks BJ, Naismith RT, et al. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2015;1. doi:10.1177/2055217315623800
BibTeX
@article{Alvarez2015,
author = {Alvarez, Enrique and Piccio, Laura and Mikesell, Robert J and Trinkaus, Kathryn and Parks, Becky J and Naismith, Robert T and Cross, Anne H},
title = {Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures},
journal = {Multiple Sclerosis Journal - Experimental, Translational and Clinical},
year = {2015},
volume = {1},
doi = {10.1177/2055217315623800}
}
EUVIMED